German-Suitable B (02526) opened high on the first day of listing and rose by more than 120% during the trading day.

On March 30th, the Hong Kong stock "Medical Imaging Large Model Platform First Stock" Dase-B (02526) officially started trading, with a strong performance on the first day. The stock price opened high and continued to rise, reaching a high of 226 Hong Kong dollars during trading, with the highest increase of 128.28%. As of the time of writing, the stock was trading at 202.00 Hong Kong dollars per share, with an increase of 104.04%. Looking back at the performance of the gray market last Friday, Dase also saw active trading. In the gray market trading on March 27th, Dase's stock price opened high and continued to rise, with a one-sided surge, reaching a high of 208 Hong Kong dollars, a surge of over 110%, showing strong buying sentiment. As a rare pure AI large model target in the Hong Kong stock market, Dase Bio, with its core medical imaging large model platform, has become one of the few new stocks with the "Dream Rate" characteristic in the AI base large model track since 2026. The company launched the iMedImage Medical Imaging General Large Model in 2025, creating the world's first billion-parameter cross-modal medical imaging base model. This model breaks through the limitations of traditional medical imaging AI single modes, covering 19 medical imaging modalities such as CT, MRI, ultrasound, pathology, chromosomes, and over 90% of clinical medical imaging scenarios, potentially changing the industry from the traditional starting from scratch research and development mode. In the first 9 months of 2025, the company achieved a staggering year-on-year revenue increase of 469.8% to 112 million yuan, with a high gross profit margin of 75.9%, and the gross profit margin for the technology licensing business reaching 96.5%. By September 2025, the company's products had been deployed in over 400 medical institutions nationwide, with an adoption rate of 40% in the top ten hospitals in China, validating the initial commercialization capabilities.